HIGHLIGHTS
- who: Strahlenther Onkol ( and colleagues from the Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China have published the article: ORIGINAL ARTICLE, in the Journal: (JOURNAL)
SUMMARY
Based on the re- search results of several phase I/II clinical trials, it is safe and feasible to use SIB-IMRT technology to escalate the total dose to a primary tumor to 59.92-70 Gy, with a single fraction dose of 2.14-2.8 Gy. After PSM: the prescription dose range of PTV-G was 59.92-66.00 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.